Canntab Therapeutics announced it has submitted its site evidence package to Health Canada for approval of their licence producer status.
Canntab Therapeutics (CSE:PILL.CN,OTCQB:CTABF) announced it has submitted its site evidence package to Health Canada for approval of its licence producer status.
As quoted in the press release:
The submission marks the final step required to obtain a licence to process cannabis at the facility, pending Health Canada review and approval.
The Company’s facility, located in Markham, Ontario, is designed and fully equipped to accommodate all manufacturing necessary to produce Canntab’s pharmaceutical grade cannabis hard pill formulations (solid oral dosage forms), which the Company believes is the future of medical cannabis. The formulations are comprised of various combinations of THC and CBD and will come in dosages of 2.5 mg, 5 mg and 10 mg, in extended release, instant release, and bi-layered solutions. Ongoing research and development into individual cannabinoids is expected to contribute additional formulations and dosage forms for future production.